在患有晚期心力衰竭的患者中注入酸
Stefano Ghio1, Egidio Traversi2, Roberto Maestri2
1Division of Cardiology, Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy.
Vascular pharmacology
|July 4, 2024
概括
酸尼托普鲁塞德输液 (SNP) 在晚期心力衰竭患者中安全改善血压. SNP可能会增强全身和 perfusion,联合使用显示更大的体重减轻,但增加肌水平.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚期心力衰竭 (AdvHF) 带来了重大管理挑战,特别是当机械支持或移植无法获得时.
- 在需要输液增强的AdvHF患者的基于证据的医疗管理中存在关键差距.
研究的目的:
- 评估在患有AdvHF的患者中注入酸的安全性和有效性 (SNP).
- 评估SNP对全身和输液的影响,有或没有无otropic支持.
主要方法:
- 对406名AdvHF患者接受夜间SNP输液的回顾性分析.
- 在55名患有低血压或低输血的患者中添加了多布他胺.
- 分析了155名经常住院的患者的数据.
主要成果:
- 不管是多布胺,SNP输注显著增加了系统血压差异 (p < 0.001).
- 结合SNP和dobutamine导致比单独SNP更大的体重减轻 (p < 0.003).
- 与SNP同时服用多布他胺与肌素水平显著增加有关 (p = 0.005).
结论:
- 化的输液是AdvHF患者的安全治疗选择.
- 在晚期心力衰竭中,SNP在改善全身和输液方面显示出潜在的有效性.
- 由于可能对脏产生影响,组合疗法需要仔细监测.
相关概念视频
Antihypertensive Drugs: Vasodilators
502
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
502
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Antianginal Drugs: Nitrates and β-Blockers
571
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571


